Long-term Efficacy of Pegtibatinase: Travere Therapeutics presented data showing that pegtibatinase significantly reduced toxic metabolite levels in patients with classical homocystinuria (HCU) over 50 weeks, with a 53.5% reduction in total homocysteine and a 67.1% reduction in methionine, while being generally well-tolerated.
Future Development Plans: The company is on track to restart enrollment in the Phase 3 HARMONY Study for pegtibatinase in 2026, aiming to establish it as the first disease-modifying therapy for classical HCU, addressing the urgent need for effective treatment options in this rare disease.
TVTX
$35.74+Infinity%1D
Analyst Views on TVTX
Wall Street analysts forecast TVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVTX is 40.09 USD with a low forecast of 31.00 USD and a high forecast of 49.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast TVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVTX is 40.09 USD with a low forecast of 31.00 USD and a high forecast of 49.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 35.850
Low
31.00
Averages
40.09
High
49.00
Current: 35.850
Low
31.00
Averages
40.09
High
49.00
Piper Sandler
Allison Bratzel
Neutral
maintain
$26 -> $35
2025-11-04
Reason
Piper Sandler
Allison Bratzel
Price Target
$26 -> $35
2025-11-04
maintain
Neutral
Reason
Piper Sandler analyst Allison Bratzel raised the firm's price target on Travere Therapeutics to $35 from $26 and keeps a Neutral rating on the shares. The firm notes Filspari had a strong Q3, with U.S. revenue of $90.9M coming in about $12M above consensus, representing +26% quarter-over-quarter growth and an impressive 155% year-over-year growth. Piper sees the upcoming regulatory decision for FSGS as the primary near-term driver for shares, with regulatory uncertainty leading the firm to remain on the sidelines.
TD Cowen
Tyler Van Buren
Buy
maintain
$30 -> $40
2025-10-31
Reason
TD Cowen
Tyler Van Buren
Price Target
$30 -> $40
2025-10-31
maintain
Buy
Reason
TD Cowen analyst Tyler Van Buren raised the firm's price target on Travere Therapeutics to $40 from $30 and keeps a Buy rating on the shares. The firm said Q3 Filspari sales of $91MM (+26% Q/Q) led to an impressive 15% beat over consensus, underscoring strong demand, PSF pull-through, and persistence.
Citi
Yigal Nochomovitz
Buy
maintain
$34 -> $48
2025-10-31
Reason
Citi
Yigal Nochomovitz
Price Target
$34 -> $48
2025-10-31
maintain
Buy
Reason
Citi analyst Yigal Nochomovitz raised the firm's price target on Travere Therapeutics to $48 from $34 and keeps a Buy rating on the shares. Citi also added an "upside 90-day catalyst watch" on Travere. The firm expects FDA approval by the action date of January 13, 2026, for Filspari for the treatment of focal segmental glomerulosclerosis. Citi believes "everything seems to be moving in a positive direction" for Travere following the Q3 report.
Evercore ISI
Outperform
to
NULL
downgrade
$45 -> $35
2025-10-01
Reason
Evercore ISI
Price Target
$45 -> $35
2025-10-01
downgrade
Outperform
to
NULL
Reason
Evercore ISI lowered the firm's price target on Travere Therapeutics to $35 from $45 and keeps an Outperform rating on the shares. All eyes are on the FSGS PDUFA on January 13, 2026, given that this has "implications for the whole renal field," according to the analyst, who sees this as an up 30%-35% or down 60%-65% event for Travere.
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
